For the quarter, the company -- which reports in Canadian dollars -- booked 98.9 million Canadian dollars in net revenue. This was up by 52% over the previous quarter and 415% higher on a year-over-year basis. It was also on the back of an 86% quarter-over-quarter increase in production volume, to 29,034 kilos. The rise in production was due in no small measure to the addition of two new cultivation facilities.
Aurora's average net selling price per gram for consumer cannabis fell 6% sequentially to land at CA$5.14. That for medical cannabis held steady at CA$8.51.
The highest share (47%) of the company's cannabis revenue, not surprisingly, came from the consumer segment. Recreational marijuana has been legal in Aurora's native Canada for nearly a year. Medical cannabis comprised 31%, while wholesale bulk product made up the remainder.
In terms of profitability, Aurora's headline net loss for the quarter came in at CA$2.3 million (less than CA$0.01 per share), a vast improvement over the Q3 deficit of CA$160.2 million but quite some distance from the Q4 2018 net profit of CA$79.9 million.
On average, analysts who track the stock were expecting a top-line result of CA$108 million, and a per-share adjusted net loss of CA$0.06 (Aurora has not yet provided a per-share net loss figure for Q4). The company had guided investors to expect CA$100 million to CA$107 million on the top line, and production available for sale toward the upper end of the 25,000 to 30,000 kilos range.
For the entirety of fiscal 2019, Aurora's net revenue was CA$247.9 million, more than four times higher than the CA$55.2 million it posted in the previous year. The company produced 57,442 kilos of product in fiscal 2018, a 920% year-over-year increase. On the bottom line the company flipped to a net loss of CA$297.9 million from a net profit of CA$69.2 million in 2018.
The company did not provide guidance for future periods in its earnings release.
Aurora's stock price is down by 9% in after-market trading in the wake of the results announcement.